Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Droloxifene (3-Hydroxytamoxifen) is an oral bioactive selective estrogen receptor modulator (SERM) that functions as an ER antagonist in breast tissue and an ER agonist in bone. It is an analogue of tamoxifen. It inhibits bone resorption and turnover, raises luteal cell apoptosis, has antiestrogenic and anti-implantation properties, and lowers E-selectin levels.
ln Vitro |
Droloxifene (10 nM; 16-18 hours) induces apoptosis in MCF-7 cells[1].
|
---|---|
ln Vivo |
Droloxifene (5-20 mg/kg; p.o.; daily for 4 weeks) enhances the BMD of DFM at 10 mg/kg and totally stops the BMC and BMD of DFM from declining when ovariectomized (OVX) is administered at 20 mg/kg/day[3].
|
Animal Protocol |
5-month-old sham-operate rats[3]
5, 10, 20 mg/kg Oral; daily for 4 weeks |
References |
|
Molecular Formula |
C26H29NO2
|
---|---|
Molecular Weight |
387.51396
|
Exact Mass |
387.22
|
Elemental Analysis |
C, 80.59; H, 7.54; N, 3.61; O, 8.26
|
CAS # |
82413-20-5
|
Related CAS # |
97752-20-0 (citrate);82413-20-5;
|
Appearance |
Solid powder
|
SMILES |
CC/C(=C(/C1=CC=C(C=C1)OCCN(C)C)\C2=CC(=CC=C2)O)/C3=CC=CC=C3
|
InChi Key |
ZQZFYGIXNQKOAV-OCEACIFDSA-N
|
InChi Code |
InChI=1S/C26H29NO2/c1-4-25(20-9-6-5-7-10-20)26(22-11-8-12-23(28)19-22)21-13-15-24(16-14-21)29-18-17-27(2)3/h5-16,19,28H,4,17-18H2,1-3H3/b26-25+
|
Chemical Name |
3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
|
Synonyms |
Droloxifene; K 060E; K060E; K-060E; K 21060E; K 21060E
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~50 mg/mL (~129.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (12.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5806 mL | 12.9029 mL | 25.8058 mL | |
5 mM | 0.5161 mL | 2.5806 mL | 5.1612 mL | |
10 mM | 0.2581 mL | 1.2903 mL | 2.5806 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Effects of droloxifene and estrogen on plasma lipids. TC indicates total plasma cholesterol; TG, triglycerides. Arterioscler Thromb Vasc Biol . 2000 Jun;20(6):1606-12. td> |
Effects of droloxifene and estrogen on brachial artery flow-mediated dilation (percent change in diameter). Arterioscler Thromb Vasc Biol . 2000 Jun;20(6):1606-12. td> |